Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_31a025d7e3afbc084b49285c33d27b44 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-353 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-553 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-553 |
filingDate |
2006-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fe2544e55c13e122ea633700ba4a9b7 |
publicationDate |
2008-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2008214521-A1 |
titleOfInvention |
Sensitization of Drug-Resistant Lung Caners to Protein Kinase Inhibitors |
abstract |
The present invention relates to a method of treating non-small cell lung cancer with FLT-3 kinase inhibitor such as PKC412. The invention also relates to a pharmaceutical combination of a FLT-3 kinase inhibitor and an activator of permeabilization of the mitochondrial outer membrane, such as an activator of BAK. It also relates to the use of a pharmaceutical combination of an activator of permeabilization of the mitochondrial outer membrane and a FLT-3 kinase inhibitor for the treatment of non-small cell lung cancer and the use of such a pharmaceutical composition for the manufacture of a medicament for the treatment of same. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014080838-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016331750-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9241941-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116355851-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023003990-A1 |
priorityDate |
2005-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |